<DOC>
	<DOCNO>NCT00089011</DOCNO>
	<brief_summary>This phase II trial study well tacrolimus mycophenolate mofetil work prevent graft-versus-host disease patient undergone total-body irradiation ( TBI ) without fludarabine phosphate follow donor peripheral blood stem cell transplant hematologic cancer . Giving low dos chemotherapy , fludarabine phosphate , TBI donor peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Tacrolimus Mycophenolate Mofetil Preventing Graft-Versus-Host Disease Patients Who Have Undergone Total-Body Irradiation With Without Fludarabine Phosphate Followed Donor Peripheral Blood Stem Cell Transplant Hematologic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate incidence grade III/IV graft-versus-host disease ( GVHD ) condition 200 centigray ( cGy ) TBI alone Fludarabine ( fludarabine phosphate ) /200 cGy TBI follow tacrolimus ( Tac ) /mycophenolate mofetil ( MMF ) immunosuppression patient hematologic malignancy . II . To estimate incidence chronic extensive GVHD . SECONDARY OBJECTIVES : I . To estimate incidence graft rejection . II . To estimate overall survival 1-year conditioning . III . To evaluate incidence grade II-IV acute GVHD . IV . To evaluate rate disease progression and/or relapse-related mortality . V. To estimate rate duration steroid use treatment chronic GVHD . OUTLINE : Patients assign 1 2 treatment arm . ARM I ( nonmyeloablative conditioning fludarabine phosphate TBI ) : Patients receive fludarabine phosphate intravenously ( IV ) day -4 -2 undergo TBI day 0 . ARM II ( nonmyeloablative conditioning TBI ) : Patients undergo TBI day 0 . All patient undergo allogeneic peripheral blood stem cell transplantation day 0 receive tacrolimus orally ( PO ) every 12 hour day -3 180 , taper day 56 , tacrolimus IV unable tolerate PO ; mycophenolate mofetil PO every 12 hour day 0-27 mycophenolate mofetil IV unable tolerate PO . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 2 year annually 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patient must eligible conventional allogeneic hematopoietic cell transplantation ( HCT ) must disease expect stable least 100 day without chemotherapy ; patient hematologic malignancy treatable HCT B cell malignancy except curable autologous transplant include ; patient eligible active disease specific protocol may enrol protocol ; patient include follow Diffuse large B cell nonHodgkin lymphoma ( NHL ) aggressive lymphoma eligible conventional myeloablative HCT autologous HCT Low grade NHL &lt; 6 month duration complete response ( CR ) course conventional therapy Mantle cell NHL may treat first CR Chronic lymphocytic leukemia ( CLL ) must either 1 ) fail meet National Cancer Institute ( NCI ) Working Group criteria complete partial response therapy regimen contain fludarabine phosphate ( FLU ) ( another nucleoside analog , e.g . 2chlorodeoxyadenosine [ 2CDA ] , pentostatin ) experience disease relapse within 12 month complete therapy regimen contain FLU ( another nucleoside analog ) ; 2 ) fail FLUcyclophosphamide ( CY ) Rituximab ( FCR ) combination chemotherapy time point ; 3 ) `` 17p deletion '' cytogenetic abnormality ; patient receive induction chemotherapy could transplant 1st CR ; 4 ) patient diagnosis CLL ( small lymphocytic lymphoma ) diagnosis CLL progress prolymphocytic leukemia ( PLL ) , Tcell CLL PLL Hodgkin lymphoma ( HL ) must receive failed frontline therapy ; patient must fail eligible autologous transplant Multiple myeloma ( MM ) follow plan autologous transplant equivalent highdose therapy without graft , follow fail prior autograft Acute myeloid leukemia ( AML ) must &lt; 5 % marrow blast time transplant Acute lymphoblastic leukemia ( ALL ) must &lt; 5 % marrow blast time transplant Chronic myelogenous leukemia ( CML ) patient accept beyond first chronic phase ( CP1 ) receive previous myelosuppressive chemotherapy HCT , &lt; 5 % marrow blast time transplant Myelodysplastic syndromes/myeloproliferative disorder ( MDS/MPD ) must receive previous myelosuppressive chemotherapy HCT , &lt; 5 % marrow blast time transplant Waldenstrom 's macroglobulinemia must fail 2 course therapy Myelosuppressive chemotherapy must discontinue three week prior condition exception hydroxyurea imatinib Patients &lt; 12 year old must approve participate institution ' patient review committee Patient Care Conference ( PCC ) Fred Hutchinson Cancer Research Center ( FHCRC ) FHCRC principal investigator Patient refuse treated conventional HCT protocol ; inclusion criterion , transplant must approve participate institution 's patient review committee Patient Care Conference ( PCC ) FHCRC FHCRC principal investigator Patients human leukocyte antigen ( HLA ) match related donor Patients renal failure eligible ; however , patient renal compromise ( serum creatinine &gt; 2.0 ) likely compromise renal function may require hemodialysis ( may permanent ) due need maintain adequate serum tacrolimus level DONOR : Related donor HLA genotypically identical least one haplotype may phenotypically genotypically identical allele level HLAA , B , C , DRB1 , DQB1 DONOR : Donor must consent filgrastim ( GCSF ) administration leukapheresis DONOR : Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) Eligible high priority curative autologous transplant Patient rapidly progressive , aggressive NHL unless minimal disease state Patients chronic myelomonocytic leukemia ( CMML ) Life expectancy severely limited disease malignancy Any current central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy Presence circulate leukemic blast ( peripheral blood ) detect standard pathology patient AML , ALL CML Fertile men woman unwilling use contraceptive 12 month post treatment Female patient pregnant breastfeed Human immunodeficiency virus ( HIV ) positive patient Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) ; exclusion apply patient nonhematologic malignancy require therapy Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence ; exclusion apply patient nonhematologic malignancy require therapy Fungal pneumonia radiological progression receipt amphotericin formulation moldactive azoles great 1 month Karnofsky score &lt; 50 adult patient LanskyPlay performance score &lt; 50 pediatric patient Symptomatic coronary artery disease ejection fraction &lt; 35 % cardiac failure require therapy ( , unable obtain ejection fraction , shorten fraction &lt; 26 % ) ; ejection fraction require age &gt; 50 year history anthracycline exposure history cardiac disease ; patient shorten fraction &lt; 26 % may enrol approve cardiologist Poorly control hypertension Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 30 % , total lung capacity ( TLC ) &lt; 30 % , forced expiratory volume one second ( FEV1 ) &lt; 30 % and/or receive supplementary continuous oxygen ; FHCRC principal investigator ( PI ) study must approve enrollment patient pulmonary nodule Liver function abnormality : Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension bridge fibrosis , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Patients active bacterial fungal infection unresponsive medical therapy DONOR : Age le 12 year DONOR : Identical twin DONOR : Pregnancy DONOR : Infection HIV DONOR : Known allergy filgrastim ( GCSF ) DONOR : Current serious systemic illness would result increase risk GCSF mobilization harvest peripheral blood stem cell ( PBSC )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>